Merck(US:MRK)2025-10-30 13:00Financial Performance & Outlook - Worldwide sales for Q3 2025 reached $17.3 billion, a 4% increase nominally and 3% increase ex-FX [13, 26] - Human Health sales were $15.6 billion, up 4% nominally and 3% ex-FX [26] - Animal Health sales reached $1.6 billion, a 9% nominal increase and 7% ex-FX [26] - KEYTRUDA sales increased by 8% to $8.1 billion, driven by strong demand [27] - GARDASIL sales decreased by 25% to $1.7 billion, primarily due to China [32] - The company updated its 2025 revenue guidance to $64.5B to $65.0B, implying a 1% nominal increase (1% to 2% ex-FX) [45] - Non-GAAP EPS for Q3 2025 was $2.58, a 64% increase [44] Pipeline & Business Development - The company is investing over $70 billion in U S manufacturing and R&D beginning in 2025 [12] - The company completed the strategic acquisition of Verona Pharma in October [18] - The company anticipates >$50B commercial opportunity by mid-2030s from recent launches and late-phase pipeline [22]